Jonathan Corbett, MD
Urology · Worthington, OHNPI 1174919948
Payments from drug & device makers
Across 140 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$870
- Dendreon Pharmaceuticals LLC$571
- Boston Scientific$412
- Urogen Pharma, Inc.$291
- Medtronic$268
- AbbVie$236
- plus $2K from 24 others
What the payments were for
- Travel & lodging$68615%
- Food & beverage$4,00685%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 6 | $870 |
| Dendreon Pharmaceuticals LLC | 18 | $571 |
| Boston Scientific | 6 | $412 |
| Urogen Pharma, Inc. | 9 | $291 |
| Medtronic(2 entities) | 5 | $268 |
| AbbVie | 13 | $236 |
| Sumitomo Pharma America, Inc. | 11 | $229 |
| Johnson & Johnson | 10 | $202 |
| Teleflex LLC | 3 | $173 |
| Merck | 3 | $169 |
| Pfizer | 8 | $151 |
| Blue Earth Diagnostics | 2 | $140 |
| Astellas Pharma US Inc | 8 | $138 |
| Stryker | 1 | $101 |
| Immunitybio, Inc. | 4 | $98 |
| Bayer | 4 | $86 |
| Endo Pharmaceuticals Inc. | 6 | $86 |
| Myovant Sciences Inc. | 3 | $70 |
| Progenics Pharmaceuticals, Inc. | 3 | $65 |
| AstraZeneca | 3 | $57 |
| Tolmar Pharmaceuticals, Inc. | 1 | $53 |
| Olympus America Inc. | 3 | $51 |
| Endo USA, Inc. | 2 | $47 |
| Laborie Medical Technologies Corp. | 2 | $34 |
| Vertex | 1 | $28 |
| Sun Pharmaceutical Industries Inc. | 1 | $26 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$828
- PROVENGE$148
- UroLift$141
- INTERSTIM$133
- AMS$120
- GENERAL ERECTILE DYSFUNCTION$118
- Axumin$112
- KEYTRUDA$110
- 1588 HD 3 CHIP CAMERA$101
How this compares
$4,713 in reported general payments places this provider in the 60th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 108 | $1,318,701 |
| ErleadaApalutamide | 55 | $808,885 |
| Abiraterone Acetate | 137 | $382,398 |
| NubeqaDarolutamide | 18 | $231,859 |
| LynparzaOlaparib | 12 | $179,053 |
| OrgovyxRelugolix | 52 | $140,895 |
| MyrbetriqMirabegron | 115 | $73,273 |
| GemtesaVibegron | 38 | $27,958 |
| Tamsulosin Hcl | 452 | $5,439 |
| Oxybutynin Chloride ErOxybutynin Chloride | 243 | $4,726 |
| Testosterone Cypionate | 56 | $2,335 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,853 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 108 | $1,768 |
| Methenamine Hippurate | 24 | $1,752 |
| Trospium Chloride ErTrospium Chloride | 18 | $1,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $138 | $1,391,975223 claims |
| Johnson & JohnsonErleada | $202 | $808,88555 claims |
| BayerNubeqa | $86 | $231,85918 claims |
| AstraZenecaLynparza | $57 | $179,05312 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $229 | $168,85490 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 485 urology providers in Ohio.
Other urology in Worthington
- Ronney AbazaWorthington$399K
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Benjamin MartinGahanna$1.1M
- Howard GoldmanCleveland$747K
- Jihad KaoukCleveland$696K
- Raymond RackleyCleveland$695K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.